{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T06:44:13Z","timestamp":1790837053100,"version":"4.1.0"},"reference-count":48,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T00:00:00Z","timestamp":1772150400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Allergy"],"abstract":"<jats:p>Managing chronic rhinosinusitis with nasal polyps (CRSwNP) poses challenges, especially when conventional treatments fail to achieve adequate symptom control. CRSwNP is often marked by type 2 inflammation, and a large number of patients have other comorbid type 2 conditions, such as asthma. Currently, 4 biologics have been approved to treat CRSwNP\u2014dupilumab, omalizumab, mepolizumab, and stapokibart (stapokibart is approved in China but not by the US Food and Drug Administration)\u2014with additional promising therapies currently under development. Biologics can enhance the quality of life for CRSwNP patients, reduce the need for systemic corticosteroid therapy and endoscopic sinus surgery (ESS), and improve the management of comorbid conditions. We review clinical trials and real-world data on the effectiveness and safety of biologics for CRSwNP, compare biologic therapy and ESS, and explore the switching and simultaneous use of biologics.<\/jats:p>","DOI":"10.3389\/falgy.2026.1759649","type":"journal-article","created":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T06:50:50Z","timestamp":1772175050000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Advance in biologics for chronic rhinosinusitis with nasal polyps"],"prefix":"10.3389","volume":"7","author":[{"given":"Yiming","family":"Di","sequence":"first","affiliation":[{"name":"Department of Otorhinolaryngology Head and Neck Surgery, The Third Affiliated Hospital of Sun Yat-sen University","place":["Guangzhou, China"]},{"name":"Zhongshan School of Medicine, Sun Yat-sen University","place":["Guangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruizhi","family":"Zeng","sequence":"additional","affiliation":[{"name":"Zhongshan School of Medicine, Sun Yat-sen University","place":["Guangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Otorhinolaryngology Head and Neck Surgery, The Third Affiliated Hospital of Sun Yat-sen University","place":["Guangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Wu","sequence":"additional","affiliation":[{"name":"Zhongshan School of Medicine, Sun Yat-sen University","place":["Guangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingwu","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Otorhinolaryngology Head and Neck Surgery, The Third Affiliated Hospital of Sun Yat-sen University","place":["Guangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,2,27]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1002\/alr.22741","article-title":"International consensus statement on allergy and rhinology: rhinosinusitis 2021","volume":"11","author":"Orlandi","year":"2021","journal-title":"Int Forum Allergy Rhinol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4193\/Rhin20.401","article-title":"European Position paper on rhinosinusitis and nasal polyps 2020","volume":"58","author":"Fokkens","year":"2020","journal-title":"Rhinology"},{"key":"B3","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/j.jaip.2016.04.012","article-title":"Chronic rhinosinusitis with nasal polyps","volume":"4","author":"Stevens","year":"2016","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B4","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.jaci.2020.11.013","article-title":"EUFOREA Expert board meeting on uncontrolled severe chronic rhinosinusitis with nasal polyps (CRSwNP) and biologics: definitions and management","volume":"147","author":"Bachert","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1016\/S0140-6736(19)31881-1","article-title":"Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials","volume":"394","author":"Bachert","year":"2019","journal-title":"Lancet"},{"key":"B6","doi-asserted-by":"publisher","first-page":"3104","DOI":"10.1002\/lary.32205","article-title":"Sustained efficacy and low rate of adverse events of dupilumab in type-2 CRSwNP over 48\u2009months","volume":"135","author":"Orlando","year":"2025","journal-title":"Laryngoscope"},{"key":"B7","doi-asserted-by":"publisher","first-page":"2684","DOI":"10.1111\/all.15796","article-title":"Two-year results of tapered dupilumab for CRSwNP demonstrates enduring efficacy established in the first 6\u2009months","volume":"78","author":"van der Lans","year":"2023","journal-title":"Allergy"},{"key":"B8","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1001\/jama.2025.12515","article-title":"Stapokibart for severe uncontrolled chronic rhinosinusitis with nasal polyps: the CROWNS-2 randomized clinical trial","volume":"334","author":"Shen","year":"2025","journal-title":"Jama"},{"key":"B9","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/j.jaci.2020.05.032","article-title":"Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trials","volume":"146","author":"Gevaert","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1016\/j.jaci.2021.07.045","article-title":"Long-term efficacy and safety of omalizumab for nasal polyposis in an open-label extension study","volume":"149","author":"Gevaert","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"5773","DOI":"10.1007\/s00405-024-08790-y","article-title":"The use of biologics in patients suffering from chronic rhinosinusitis with nasal polyps - a 4-year real life observation","volume":"281","author":"Frankenberger","year":"2024","journal-title":"Eur Arch Otorhinolaryngol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"448","DOI":"10.3390\/medicina60030448","article-title":"The effectiveness of biological agents on chronic rhinosinusitis with nasal polyposis in patients with comorbid asthma: a multicenter real-life study from t\u00fcrkiye","volume":"60","author":"Demir","year":"2024","journal-title":"Medicina"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1016\/S2213-2600(21)00097-7","article-title":"Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"9","author":"Han","year":"2021","journal-title":"Lancet Respir Med"},{"key":"B14","doi-asserted-by":"publisher","first-page":"576","DOI":"10.4193\/Rhin24.156","article-title":"Mepolizumab in CRSwNP\/ECRS and NP: the phase III randomised MERIT trial in Japan, China, and Russia","volume":"62","author":"Fujieda","year":"2024","journal-title":"Rhinology"},{"key":"B15","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1016\/S0140-6736(25)00197-7","article-title":"Efficacy and safety of twice per year depemokimab in chronic rhinosinusitis with nasal polyps (ANCHOR-1 and ANCHOR-2): phase 3, randomised, double-blind, parallel trials","volume":"405","author":"Gevaert","year":"2025","journal-title":"Lancet"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1016\/j.jaci.2021.08.030","article-title":"Efficacy and safety of benralizumab in chronic rhinosinusitis with nasal polyps: a randomized, placebo-controlled trial","volume":"149","author":"Bachert","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1111\/all.16519","article-title":"Chinese Position paper on biologic therapy for chronic rhinosinusitis with nasal polyps","volume":"80","author":"Xian","year":"2025","journal-title":"Allergy"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1056\/NEJMoa2414482","article-title":"Tezepelumab in adults with severe chronic rhinosinusitis with nasal polyps","volume":"392","author":"Lipworth","year":"2025","journal-title":"N Engl J Med"},{"key":"B19","doi-asserted-by":"publisher","first-page":"e047344","DOI":"10.1136\/bmjopen-2020-047344","article-title":"Efficacy and safety of omalizumab in chronic rhinosinusitis with nasal polyps: a systematic review and meta-analysis of randomised controlled trials","volume":"11","author":"Wu","year":"2021","journal-title":"BMJ Open"},{"key":"B20","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1159\/000519228","article-title":"Which is the best biologic for nasal polyps: dupilumab, omalizumab, or mepolizumab? A network meta-analysis","volume":"183","author":"Wu","year":"2022","journal-title":"Int Arch Allergy Immunol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1159\/000521859","article-title":"Efficacy and safety of anti-interleukin-5 therapies in chronic rhinosinusitis with nasal polyps: a systematic review and meta-analysis of randomized controlled trials","volume":"183","author":"Wang","year":"2022","journal-title":"Int Arch Allergy Immunol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1111\/all.14610","article-title":"Treatment-emergent adverse events in dupilumab-treated patients with allergic diseases: a meta-analysis","volume":"76","author":"Chen","year":"2021","journal-title":"Allergy"},{"key":"B23","doi-asserted-by":"publisher","first-page":"e70114","DOI":"10.1002\/clt2.70114","article-title":"Which is the best biologic for nasal polyps: an updated network meta-analysis","volume":"15","author":"Xu","year":"2025","journal-title":"Clin Transl Allergy"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1016\/S2213-2600(25)00287-5","article-title":"Dupilumab versus omalizumab in patients with chronic rhinosinusitis with nasal polyps and coexisting asthma (EVEREST): a multicentre, randomised, double-blind, head-to-head phase 4 trial","volume":"13","author":"De Corso","year":"2025","journal-title":"Lancet Respir Med"},{"key":"B25","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1016\/j.anai.2021.01.012","article-title":"Dupilumab improves upper and lower airway disease control in chronic rhinosinusitis with nasal polyps and asthma","volume":"126","author":"Laidlaw","year":"2021","journal-title":"Ann Allergy Asthma Immunol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1001\/jama.2015.19330","article-title":"Effect of subcutaneous dupilumab on nasal polyp burden in patients with chronic sinusitis and nasal polyposis A randomized clinical trial","volume":"315","author":"Bachert","year":"2016","journal-title":"JAMA"},{"key":"B27","doi-asserted-by":"publisher","first-page":"e12169","DOI":"10.1002\/clt2.12169","article-title":"Adverse events for biologics in patients with CRSwNP: a meta-analysis","volume":"12","author":"Shen","year":"2022","journal-title":"Clin Transl Allergy"},{"key":"B28","doi-asserted-by":"publisher","first-page":"104705","DOI":"10.1016\/j.amjoto.2025.104705","article-title":"Analysis of adverse reaction characteristics of four biologics for the treatment of chronic sinusitis with nasal polyps: a descriptive analysis from WHO-VigiAccess","volume":"46","author":"Fang","year":"2025","journal-title":"Am J Otolaryngol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1159\/000534545","article-title":"Characterizing adverse events of biologic treatment of T2 disease: a disproportionality analysis of the FDA adverse event reporting system","volume":"85","author":"Stack","year":"2023","journal-title":"ORL"},{"key":"B30","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.jaip.2024.10.036","article-title":"Dupilumab use in patients with hypereosinophilic syndromes: a multicenter case series and review of the literature","volume":"13","author":"Ezekwe","year":"2025","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1618","DOI":"10.1002\/alr.23453","article-title":"Rheumatic adverse events associated with biologic therapy for chronic rhinosinusitis: a systematic review and meta-analysis","volume":"14","author":"Xiao","year":"2024","journal-title":"Int Forum Allergy Rhinol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1177\/19458924241272978","article-title":"Comparative effectiveness of dupilumab versus Sinus surgery for chronic rhinosinusitis with polyps: systematic review and a meta-analysis","volume":"38","author":"Kim","year":"2024","journal-title":"Am J Rhinol Allergy"},{"key":"B33","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1002\/alr.22951","article-title":"Outcomes of dupilumab treatment versus endoscopic sinus surgery for chronic rhinosinusitis with nasal polyps","volume":"12","author":"Dharmarajan","year":"2022","journal-title":"Int Forum Allergy Rhinol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1111\/coa.14172","article-title":"Comparative real-world outcomes of dupilumab versus endoscopic sinus surgery in the treatment of severe CRSwNP patients","volume":"49","author":"De Corso","year":"2024","journal-title":"Clin Otolaryngol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1002\/alr.23059","article-title":"A comparative analysis of endoscopic sinus surgery versus biologics for treatment of chronic rhinosinusitis with nasal polyposis","volume":"13","author":"Miglani","year":"2023","journal-title":"Int Forum Allergy Rhinol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1002\/alr.22936","article-title":"Economic evaluation of dupilumab versus endoscopic Sinus surgery for the treatment of chronic rhinosinusitis with nasal polyps","volume":"12","author":"Parasher","year":"2022","journal-title":"Int Forum Allergy Rhinol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1007\/s11882-023-01106-w","article-title":"Omalizumab treatment in uncontrolled asthma and CRSwNP patients, with previous endoscopic Sinus surgery, to improve quality of life and endoscopic outcomes: a two-year real-life study","volume":"23","author":"Maza-Solano","year":"2023","journal-title":"Curr Allergy Asthma Rep"},{"key":"B38","doi-asserted-by":"publisher","first-page":"e12269","DOI":"10.1002\/clt2.12269","article-title":"Comparative short-term efficacy of endoscopic sinus surgery and biological therapies in chronic rhinosinusitis with nasal polyps: a network meta-analysis","volume":"13","author":"Chen","year":"2023","journal-title":"Clin Transl Allergy"},{"key":"B39","doi-asserted-by":"publisher","first-page":"e79742","DOI":"10.7759\/cureus.79742","article-title":"Comparing medical and surgical management of chronic rhinosinusitis: a systematic review of dupilumab and endoscopic Sinus surgery","volume":"17","author":"Weissman","year":"2025","journal-title":"Cureus"},{"key":"B40","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1002\/alr.23466","article-title":"Switching biologics in chronic rhinosinusitis with nasal polyps: a multicenter Canadian experience","volume":"15","author":"Dorling","year":"2025","journal-title":"Int Forum Allergy Rhinol"},{"key":"B41","doi-asserted-by":"publisher","first-page":"320","DOI":"10.4193\/Rhin22.408","article-title":"Efficacy and safety of switching between biologics in chronic rhinosinusitis with nasal polyps or N-ERD","volume":"61","author":"Brkic","year":"2023","journal-title":"Rhinology"},{"key":"B42","doi-asserted-by":"publisher","first-page":"194","DOI":"10.4193\/Rhin22.489","article-title":"EPOS\/EUFOREA update on indication and evaluation of biologics in chronic rhinosinusitis with nasal polyps 2023","volume":"61","author":"Fokkens","year":"2023","journal-title":"Rhinology"},{"key":"B43","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1080\/1744666X.2023.2218617","article-title":"Evaluation of switching or simultaneous use of biologic treatment in patients with severe chronic rhinosinusitis with nasal polyps and severe asthma. Considerations in clinical decision making","volume":"19","author":"Otten","year":"2023","journal-title":"Expert Rev Clin Immunol"},{"key":"B44","doi-asserted-by":"publisher","first-page":"3017","DOI":"10.1007\/s00405-024-08461-y","article-title":"Switching of biological therapy to dupilumab in comorbid patients with severe asthma and CRSwNP","volume":"281","author":"Rosso","year":"2024","journal-title":"Eur Arch Otorhinolaryngol"},{"key":"B45","doi-asserted-by":"publisher","first-page":"100512","DOI":"10.1016\/j.xocr.2023.100512","article-title":"A case of intractable chronic rhinosinusitis without nasal polyps leading remission after treatment switching from anti-IL-5 to anti-IL-4R\u03b1 monoclonal antibody","volume":"27","author":"Oka","year":"2023","journal-title":"Otolaryngol Case Rep"},{"key":"B46","doi-asserted-by":"publisher","first-page":"6057","DOI":"10.1007\/s00405-025-09559-7","article-title":"An overview of switching biological therapies for chronic rhinosinusitis with nasal polyposis (CRSwNP)","volume":"282","author":"Alharbi","year":"2025","journal-title":"Eur Arch Otorhinolaryngol"},{"key":"B47","doi-asserted-by":"publisher","first-page":"2411018","DOI":"10.1080\/07853890.2024.2411018","article-title":"Efficacy of dupilumab on chronic rhinosinusitis with nasal polyps and concomitant asthma in biologic-naive and biologic-pretreated patients","volume":"56","author":"Dom\u00ednguez-Sosa","year":"2024","journal-title":"Ann Med"},{"key":"B48","doi-asserted-by":"publisher","first-page":"6883","DOI":"10.3390\/jcm13226883","article-title":"Monoclonal antibody switching in biologic treatment of chronic rhinosinusitis with nasal polyps","volume":"13","author":"Habenbacher","year":"2024","journal-title":"J Clin Med"}],"container-title":["Frontiers in Allergy"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/falgy.2026.1759649\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T06:50:50Z","timestamp":1772175050000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/falgy.2026.1759649\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,27]]},"references-count":48,"alternative-id":["10.3389\/falgy.2026.1759649"],"URL":"https:\/\/doi.org\/10.3389\/falgy.2026.1759649","relation":{},"ISSN":["2673-6101"],"issn-type":[{"value":"2673-6101","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,27]]},"article-number":"1759649"}}